Surveillance and Screening of AROs (Antimicrobial Resistant Organisms)
AROs: Presentations
Weds 18 June 2014 | Thurs 19 June 2014 | Fri 20 June 2014
Surveillance and Screening for Antimicrobial Resistant Organisms (AROs) 2014 - Final Program
Wednesday, 18 June 2014
08:00 – 08:15
- Opening Remarks
Dr. John Conly and Dr. James Talbot
http://vimeo.com/channels/910470/99417520
08:15 – 09:45
QUESTION 1: Overview
a) What are AROs? What is their incidence and prevalence (in health care facilities and in the community)? (Global, US, Canadian, and Alberta perspectives) Why are they a problem, globally and in Canada - what burden do they impose on patients and the health system?
- Incidence and Prevalence of AROs in Health Facilities and in the Community
Pilar Ramon-Pardo, MD, PhD
Download Presentation
http://vimeo.com/channels/910470/99409734 - What are Antimicrobial Resistant Organisms (AROs)? - Canadian Perspectives
Howard Njoo, MD, MHSc
Download Presentation
http://vimeo.com/channels/910470/99410306
b) Where do AROs come from (genetics and evolution)? How big a factor is the use of antimicrobials, and what is the contribution from various settings (healthcare, home, agriculture)?
- Can anything be done to prevent antibiotic resistance development?
Julian Davies, BSc, PhD, FRS
Download Presentation
http://vimeo.com/channels/910470/99410307 - Antimicrobial Drug Use in Animals as a Driver of Resistance
Scott McEwen, DVM, DVSc, Dip ACVP
Download Presentation
http://vimeo.com/channels/910470/99410308 - Questions and Answers 1
Dr. Pilar Ramon-Pardo, Dr. Howard Njoo, Dr. Julian Davies, and Dr. Scott McEwen
http://vimeo.com/channels/910470/100010049
10:00 – 11:15
c) What is surveillance; what is screening? How are they related?
- What is Surveillance? What is Screening? How are They Related?
Joel Kettner, MD, MSc, FRCSC, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99410309
d) What can we learn from the experience of other jurisdictions? (International, US, Canadian, and Alberta perspectives) Why does control of AROs vary so much? - e.g., is mandatory public reporting of data on AROs helpful?
- Surveillance for Antibiotic Resistant Organisms in Canadian Hospitals
Andrew Simor, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99410310 - What Can We Learn from Other Jurisdictions?
Robert Weinstein, MD
Download Presentation
http://vimeo.com/channels/910470/99414532 - Questions and Answers 1 (continued)
Dr. Joel Kettner, Dr. Andrew Simor, and Dr. Robert Weinstein
http://vimeo.com/channels/910470/100010051
12:15 – 13:00
QUESTION 2: Surveillance
a) Why should we conduct surveillance? What do we do based on the results? What outcomes do we want, and are we achieving them?
- Definition and Uses of Surveillance
James Talbot, PhD, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99414533
b) How should we conduct surveillance – what options are available? What are the key areas of focus for surveillance in public health?
- How do we decide where to focus surveillance?
David Patrick, MD, FRCPC, MHSc
Download Presentation
http://vimeo.com/channels/910470/99414534 - Questions and Answers 2
Dr. James Talbot and Dr. David Patrick
http://vimeo.com/channels/910470/100010052
13:00 – 14:40
QUESTION 3: Screening
a) Should we screen for AROs? Pro versus Con. Should we rely on horizontal measures only, i.e., general prevention? Should we rely on vertical measures, i.e., screen for multiple specific organisms? If we screen, what options should we use? – e.g., community vs admission; acute care vs. continuing care; patient selection; methods. If we screen, what should we do with the results, and how should we evaluate a screening program?
- Should We Screen for AROs? No!
Michael Edmond, MD, MPH, MPA
Download Presentation
http://vimeo.com/channels/910470/99414536 - controlling MRSA and multiple drug resistant organisms: experience in the Netherlands
Henri Verbrugh, MD, PhD, FIDSA
Download Presentation
http://vimeo.com/channels/910470/99414539 - To Screen or Not to Screen
Allison McGeer, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99417518 - Questions and Answers 3
Dr. Michael Edmond, Dr. Henri Verbrugh, and Dr. Allison McGeer
http://vimeo.com/channels/910470/100010053
15:00 – 16:00
b) Is there a role for decolonization, and if so, when, and how?
- Is There a Role for Decolonization?
Susan Huang, MD, MPH
Download Presentation
http://vimeo.com/channels/910470/99417519
c) Why do screening practices vary so much between jurisdictions?
- Why Do Antimicrobial-Resistant Organism Screening Practices Vary Across Jurisdictions?
John Jernigan, MD, MS
Download Presentation
http://vimeo.com/channels/910470/100231540 - Questions and Answers 3 (continued)
Dr. Susan Huang and Dr. John Jernigan
http://vimeo.com/channels/910470/100010054
Thursday, 19 June 2014
08:30 – 10:30
QUESTION 4: What factors can facilitate or hinder effective ARO control in practice?
a) Organizational and cultural factors (barriers and enablers)
- Barriers and Facilitators to ARO Control
Elizabeth Bryce, BSc, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99417521
b) Lab capacity – what is the burden of ARO testing on labs; is it appropriate/cost-effective relative to other demands on lab resources? Are there changes or new options available that could reduce the burden?
- ARO Screening - Lab Issues
Daniel Gregson, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99417523 - Questions and Answers 4
Dr. Elizabeth Bryce and Dr. Daniel Gregson
http://vimeo.com/channels/910470/100013495
10:00 – 12:00
QUESTION 5: Ethical and policy implications
a) What is appropriate screening for AROs in various settings?
- What is appropriate screening for ARO's in various settings?
Lindsay Nicolle, BSc, BSc (med), MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99427610
b) What are the impacts of screening on patients, and on their family members and others? – eg, can screening do harm? Does it result in patients receiving reduced care due to “leperization” (stigma) and isolation? Does it impact eligibility/placement in home care and continuing care? Do patients have the right to refuse screening (or should they)?
- Contact precautions: Friend or foe?
Anthony Harris, MD, MPH
Download Presentation
http://vimeo.com/channels/910470/99427612
c) What is the economic cost/benefit of screening from the point of view of the individual patient; health care providers; and the funder of the health care system? How do we evaluate/measure the economic value of screening?
- What is the economic cost/benefit of screening?
Barry Cookson, BDS, MBBS, MSc, HonDipHIC, FRSPH, FRCP, FFPH, FRCPath
Download Presentation
http://vimeo.com/channels/910470/99427611
d) What can patients, the public, and health care providers do to help? Would more education re: appropriate use of antibiotics help reduce the incidence of AROs, and what would be the most effective strategy? What is the appropriate role of health care providers in ensuring responsible stewardship of antimicrobials?
- The Patient's Voice
Kim Neudorf
Download Presentation
http://vimeo.com/channels/910470/99427613 - Patient Involvement
Yves Longtin, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99797007 - Questions and Answers 5
Dr. Lindsay Nicolle, Dr. Anthony Harris, Dr. Barry Cookson, Mrs. Kim Neudorf, and Dr. Yves Longtin
http://vimeo.com/channels/910470/100013496
13:00 – 14:40
QUESTION 6: Research/evidence
a) Ongoing scientific gaps for facilitating policy in healthcare
- Ongoing Gaps in Scientific Research to Facilitate ARO Policy in Healthcare
Trish Perl, MD, MSc
Download Presentation
http://vimeo.com/channels/910470/99797008
b) Outlining a Framework for ARO Screening/Surveillance Studies
- Outlining a Framework for Antimicrobial-Resistance Surveillance Studies
Eli Perencevich, MD, MS
Download Presentation
http://vimeo.com/channels/910470/99877462
c) Designing Interventional Studies for Evaluation of ARO Control Strategies
- Designing Interventional Studies for Evaluation of ARO Control Strategies
Mark Loeb, BSc, MSc, MD, FRCPC
Download Presentation
http://vimeo.com/channels/910470/99797009
d) How CIHR is Addressing Antimicrobial Resistance, Nationally, and Internationally
- How CIHR is Addressing Antimicrobial Resistance, Nationally and Internationally?
Serge Desnoyers, PhD
Download Presentation
http://vimeo.com/channels/910470/99797010 - Questions and Answers 6
Dr. Trish Perl, Dr. Eli Perencevich, Dr. Mark Loeb, and Dr. Serge Desnoyers
http://vimeo.com/channels/910470/100013497
- Questions and Answers - Open Discussion
http://vimeo.com/channels/910470/100013498
Friday, 20 June 2014
9:00 – 12:00
Reading of the Consensus Statement, open discussion, and comments on the statement
- Reading of the DRAFT Consensus Statement by Jury Chair
Tom Marrie, MD
http://vimeo.com/channels/910470/100013500
Please note that the reading of the Consensus Statement by Dr. Tom Marrie is a working draft; the final draft is available below.
SURVEILLANCE and SCREENING of AROs (Antimicrobial-Resistant Organisms) - Consensus Statement of the Jury